The Abu Dhabi Public Health Centre (ADPHC), part of the Department of Health – Abu Dhabi (DoH), has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, a leading global pharmaceutical company. This partnership aims to enhance health outcomes for patients living with chronic diseases in the Emirate of Abu Dhabi.

The collaboration focuses on improving the quality of life for individuals affected by cardiovascular, renal, and metabolic (CRM) conditions, as well as pulmonary fibrosis and stroke. With the rise of non-communicable diseases (NCDs) in the UAE, this partnership highlights the importance of joint, data-driven strategies for prevention, early detection, and public education.

Cardiovascular and metabolic diseases are significant contributors to hospitalizations and long-term health issues in the region. The MoU outlines a series of public awareness campaigns aimed at educating communities about the risks, symptoms, and management of CRM conditions and pulmonary fibrosis. The two organizations will also work together to gather data, promote healthier lifestyle choices, and encourage participation in early screening and health education initiatives.

H.E. Dr. Rashed Al Suwaidi, Director General of ADPHC, emphasized the urgent need for coordinated action to address the rising prevalence of NCDs, which are driven by sedentary lifestyles and poor dietary habits. He noted that these conditions not only affect individuals but also have broader implications for families and the healthcare system. Through the collaboration with Boehringer Ingelheim, ADPHC aims to strengthen Abu Dhabi’s public health framework, empowering communities and prioritizing prevention through education and outreach.

Ousama Alhaj, General Manager and Head of Human Pharma for the Near East and UAE at Boehringer Ingelheim, stated that meaningful transformation in healthcare requires collaboration. He expressed pride in partnering with ADPHC to promote early detection and awareness of CRM diseases, pulmonary fibrosis, and stroke. Together, they plan to advance innovative, patient-focused solutions that foster healthier communities for the present and future generations.

Chronic diseases, including cardiovascular, renal, and metabolic conditions, as well as pulmonary fibrosis and stroke, are significant contributors to morbidity and mortality in the Middle East. This partnership signifies a united commitment to addressing these challenges through collaboration, innovation, and public engagement. By working together, ADPHC and Boehringer Ingelheim aim to reduce disease incidence, enhance patient outcomes, and support a healthier, more resilient future for Abu Dhabi and the surrounding region.

The Abu Dhabi Public Health Centre (ADPHC) was established in 2019 under the Department of Health – Abu Dhabi and serves as the emirate’s dedicated authority for public and preventive health. It leads efforts to protect and promote community well-being through evidence-based programs that target communicable and non-communicable diseases, as well as occupational and environmental health. ADPHC is committed to fostering a healthier society in line with Abu Dhabi’s vision for sustainable and proactive healthcare.